Displaying 31 (all) recruiting clinical trials.
-
An Open-label Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of TAK-500 a Novel Stimulator of Interferon Genes Agonist as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
TAK-500-1001 is a phase 1/2, open-label, dose escalation and expansion study designed to determine the safety, tolerability, antitumor activity, pharmacokinetics (PK), pharmacodynamics, and preliminary ...Phase
Interventional
